FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3184865225> ?p ?o ?g. }

• W3184865225 endingPage "2284" @default.
• W3184865225 startingPage "2277" @default.
• W3184865225 abstract "Abstract Background Hidradenitis suppurativa (HS), a chronic, recurrent, debilitating skin disease, is characterized by painful, inflammatory, subcutaneous lesions of the axilla, inguinal and anogenital regions. Overall prevalence of HS is ˜1%, and the impact of disease on patient quality of life (QoL) and healthcare resource utilization (HRU) is high. Objectives To estimate the real‐world effectiveness of adalimumab (Humira®) treatment in patients with moderate‐to‐severe HS on disease severity, pain, QoL, work productivity and HRU. Methods HARMONY (Effectiveness of Adalimumab in Moderate to Severe HidrAdenitis SuppuRativa Patients – a Multi‐cOuNtry studY in Real Life Setting) is a multicentre, postmarketing observational study in adult patients with moderate‐to‐severe HS. Disease severity and QoL parameters were evaluated using validated measures at 12‐week intervals over 52 weeks of treatment. The primary endpoint was the proportion of patients achieving a Hidradenitis Suppurativa Clinical Response (HiSCR: ≥50% reduction in abscess and inflammatory nodule count, with no increase in abscess and draining fistula counts relative to baseline) at 12 weeks. Secondary endpoints were HiSCR at 24, 36 and 52 weeks and changes in QoL parameters and work productivity assessments. Analyses were conducted using as‐observed data. Results The proportion of patients reaching the primary HiSCR endpoint was 70.2% ( n = 132/188 enrolled) and remained ≥70% until study completion. There were statistically significant ( P < 0.0001) reductions in worst and average skin pain. All of the QoL measures evaluated improved significantly ( P < 0.0001) by 12 weeks of adalimumab treatment, as did work productivity assessments ( P < 0.05), and there was a ˜50% decrease in HRU between baseline and week 52. Adalimumab was well tolerated. Conclusions In this real‐world setting, adalimumab treatment of moderate‐to‐severe HS resulted in decreased disease severity and improvements in QoL and productivity. Response to adalimumab was rapid (within 12 weeks) and sustained (52 weeks). No unexpected safety signals were reported." @default.
• W3184865225 created "2021-08-02" @default.
• W3184865225 creator A5005910327 @default.
• W3184865225 creator A5016640542 @default.
• W3184865225 creator A5043799216 @default.
• W3184865225 creator A5050541601 @default.
• W3184865225 creator A5062920988 @default.
• W3184865225 creator A5073196144 @default.
• W3184865225 creator A5083992203 @default.
• W3184865225 creator A5091397515 @default.
• W3184865225 date "2021-09-25" @default.
• W3184865225 modified "2023-10-16" @default.
• W3184865225 title "Improvement in Hidradenitis Suppurativa and quality of life in patients treated with adalimumab: Real‐world results from the HARMONY Study" @default.
• W3184865225 cites W1974455447 @default.
• W3184865225 cites W1995627534 @default.
• W3184865225 cites W1996601924 @default.
• W3184865225 cites W2032390761 @default.
• W3184865225 cites W2042195767 @default.
• W3184865225 cites W2048432334 @default.
• W3184865225 cites W2065828171 @default.
• W3184865225 cites W2068176248 @default.
• W3184865225 cites W2091683231 @default.
• W3184865225 cites W2175584673 @default.
• W3184865225 cites W2329316811 @default.
• W3184865225 cites W2503109448 @default.
• W3184865225 cites W2612802596 @default.
• W3184865225 cites W2614619306 @default.
• W3184865225 cites W2755621849 @default.
• W3184865225 cites W2894720168 @default.
• W3184865225 cites W2896283288 @default.
• W3184865225 cites W2957996043 @default.
• W3184865225 cites W2958195622 @default.
• W3184865225 cites W2979544789 @default.
• W3184865225 cites W2980509403 @default.
• W3184865225 cites W2988925406 @default.
• W3184865225 cites W2997128305 @default.
• W3184865225 cites W3003122512 @default.
• W3184865225 cites W3009526876 @default.
• W3184865225 cites W3027303798 @default.
• W3184865225 doi "https://doi.org/10.1111/jdv.17551" @default.
• W3184865225 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34320249" @default.
• W3184865225 hasPublicationYear "2021" @default.
• W3184865225 type Work @default.
• W3184865225 sameAs 3184865225 @default.
• W3184865225 citedByCount "11" @default.
• W3184865225 countsByYear W31848652252021 @default.
• W3184865225 countsByYear W31848652252022 @default.
• W3184865225 countsByYear W31848652252023 @default.
• W3184865225 crossrefType "journal-article" @default.
• W3184865225 hasAuthorship W3184865225A5005910327 @default.
• W3184865225 hasAuthorship W3184865225A5016640542 @default.
• W3184865225 hasAuthorship W3184865225A5043799216 @default.
• W3184865225 hasAuthorship W3184865225A5050541601 @default.
• W3184865225 hasAuthorship W3184865225A5062920988 @default.
• W3184865225 hasAuthorship W3184865225A5073196144 @default.
• W3184865225 hasAuthorship W3184865225A5083992203 @default.
• W3184865225 hasAuthorship W3184865225A5091397515 @default.
• W3184865225 hasBestOaLocation W31848652252 @default.
• W3184865225 hasConcept C126322002 @default.
• W3184865225 hasConcept C141071460 @default.
• W3184865225 hasConcept C159110408 @default.
• W3184865225 hasConcept C16005928 @default.
• W3184865225 hasConcept C1862650 @default.
• W3184865225 hasConcept C203092338 @default.
• W3184865225 hasConcept C2776002364 @default.
• W3184865225 hasConcept C2776173921 @default.
• W3184865225 hasConcept C2779134260 @default.
• W3184865225 hasConcept C2779951463 @default.
• W3184865225 hasConcept C2780132546 @default.
• W3184865225 hasConcept C30036603 @default.
• W3184865225 hasConcept C535046627 @default.
• W3184865225 hasConcept C71924100 @default.
• W3184865225 hasConceptScore W3184865225C126322002 @default.
• W3184865225 hasConceptScore W3184865225C141071460 @default.
• W3184865225 hasConceptScore W3184865225C159110408 @default.
• W3184865225 hasConceptScore W3184865225C16005928 @default.
• W3184865225 hasConceptScore W3184865225C1862650 @default.
• W3184865225 hasConceptScore W3184865225C203092338 @default.
• W3184865225 hasConceptScore W3184865225C2776002364 @default.
• W3184865225 hasConceptScore W3184865225C2776173921 @default.
• W3184865225 hasConceptScore W3184865225C2779134260 @default.
• W3184865225 hasConceptScore W3184865225C2779951463 @default.
• W3184865225 hasConceptScore W3184865225C2780132546 @default.
• W3184865225 hasConceptScore W3184865225C30036603 @default.
• W3184865225 hasConceptScore W3184865225C535046627 @default.
• W3184865225 hasConceptScore W3184865225C71924100 @default.
• W3184865225 hasFunder F4320309117 @default.
• W3184865225 hasIssue "11" @default.
• W3184865225 hasLocation W31848652251 @default.
• W3184865225 hasLocation W31848652252 @default.
• W3184865225 hasLocation W31848652253 @default.
• W3184865225 hasOpenAccess W3184865225 @default.
• W3184865225 hasPrimaryLocation W31848652251 @default.
• W3184865225 hasRelatedWork W1514536645 @default.
• W3184865225 hasRelatedWork W1871839594 @default.
• W3184865225 hasRelatedWork W2067775822 @default.
• W3184865225 hasRelatedWork W2146549230 @default.
• W3184865225 hasRelatedWork W2604697867 @default.

• next